TL;DR
This review explores the critical challenge of delivering genome editing tools (ZFNs, TALENs, CRISPR/Cas9) into living organisms for therapeutic purposes. It summarizes current and emerging delivery strategies, highlighting the trade-offs between viral and non-viral vectors, and discusses their potential for clinical translation.
What Problem Does This Paper Address?
Therapeutic genome editing holds immense promise for correcting genetic mutations and treating diseases. However, the effectiveness of genome editing tools like ZFNs, TALENs, and CRISPR/Cas9 is severely hampered by the difficulty of delivering these large, charged molecules into target cells and tissues within a living organism. Current challenges include their low membrane permeability, susceptibility to degradation, and inefficient escape from endosomes. This paper addresses the crucial need for robust and efficient in vivo delivery systems to bridge the gap between laboratory research and clinical application of genome editing therapies.
Methods
This review is a comprehensive survey and analysis of existing and developing in vivo delivery systems for genome editing nucleases. The authors categorize delivery methods into:
- Viral Vectors: Including Adeno-associated viruses (AAVs), Adenoviral vectors (AdVs), and Lentiviral vectors (LVs). These are discussed in terms of their advantages (high efficiency, low insertional mutagenesis) and disadvantages (immunogenicity, limited cargo size for some).
- Non-Viral Vectors: Encompassing lipid nanoparticles (LNPs), liposomes, polymers, and cell-penetrating peptides (CPPs). These are highlighted for their potential to overcome viral vector limitations (lower toxicity, larger capacity) but also their current drawbacks (lower efficiency).
- Physical Methods: Briefly mentioned as primarily suitable for in vitro applications (microinjection, electroporation).
- Direct Delivery of Proteins: Explores the possibility of delivering the nuclease proteins directly, bypassing the need for genetic material delivery.
- Conjugates: Discusses methods where nucleases are chemically linked to delivery agents.
- Combined Viral and Non-Viral Delivery: Examines strategies that leverage the strengths of both approaches.
The paper analyzes these methods based on their characteristics, efficiency, toxicity, and suitability for different genome editing nucleases. It also reviews methodologies currently in clinical trials.
Datasets
Not discussed in the paper. This is a review article summarizing existing research and clinical trial information, rather than presenting new experimental data or datasets.
Key Insights and Ideas
- Delivery is the Bottleneck: The primary hurdle for translating genome editing into effective therapies is not the editing machinery itself, but the ability to deliver it precisely and efficiently to target cells in vivo.
- Viral vs. Non-Viral Trade-offs: Viral vectors offer high efficiency but face issues with immunogenicity and cargo size limitations (especially for larger nucleases like TALENs and CRISPR/Cas9). Non-viral vectors are more flexible and have larger capacities but currently struggle with lower transfection efficiency.
- CRISPR/Cas9's Size Challenge: The relatively large size of the CRISPR/Cas9 system (especially spCas9) poses a significant challenge for packaging into commonly used viral vectors like AAVs, necessitating the exploration of smaller Cas9 variants or alternative delivery strategies.
- Direct Protein Delivery Potential: Delivering the nuclease proteins directly, rather than their genetic blueprints, shows promise for reducing off-target effects and simplifying delivery, though protein stability remains a concern.
- Clinical Translation is Emerging: While many delivery systems are still in preclinical stages, some ZFN-based therapies have entered clinical trials, indicating progress towards therapeutic applications.
Key Results
The paper does not present novel experimental results but synthesizes findings from numerous studies. Key takeaways include:
- AAVs: Highly efficient for delivering smaller nucleases like ZFNs, with some clinical trials underway. However, their ~4.7 kb cargo limit restricts their use for larger systems.
- AdVs and LVs: Offer larger packaging capacities, making them more suitable for TALENs and CRISPR/Cas9, but can elicit immune responses.
- Non-viral vectors (e.g., LNPs, PEI): Show promise for larger payloads and lower immunogenicity, but their in vivo delivery efficiency is generally lower than viral vectors.
- Clinical Trials: Several ZFN-based therapies targeting HIV infection are in clinical trials. TALENs and CRISPR/Cas9 are less represented in current clinical trials, largely due to delivery challenges.
Limitations and Future Work
The authors acknowledge several limitations and suggest future directions:
- Off-Target Effects: A persistent concern for all genome editing nucleases, which can be exacerbated by delivery methods. Future work should focus on improving specificity.
- Immunogenicity: Viral vectors can trigger immune responses, limiting their repeated administration. Development of less immunogenic vectors or strategies to overcome immune barriers is needed.
- Cargo Size Limitations: Particularly for AAVs, the limited packaging capacity restricts the delivery of larger genome editing components like TALENs and CRISPR/Cas9. This drives research into smaller nuclease variants (e.g., saCas9) and high-capacity vectors.
- Efficiency and Specificity: Enhancing the efficiency of non-viral vectors and improving the tissue-specific targeting of all delivery systems are critical for clinical success.
- Need for Novel Vectors: The paper emphasizes the need for developing novel, efficient, and safe non-viral vectors for delivering ZFNs, and for improving delivery strategies for TALENs and CRISPR/Cas9.
- Combined Approaches: Future research should explore synergistic combinations of viral and non-viral strategies to leverage their respective advantages.
Summary updated